PI-RADS classification is a standardized system for interpreting prostate MRI images to assess the risk of clinically significant cancer.The PI-RADS (Prostate Imaging Reporting and Data System) is a standardized method for assessing the probability of clinically significant prostate cancer based on multiparametric MRI. Each detected lesion in the transition or peripheral zone receives a score on a 5-point scale. The assessment is based on analysis of T2-weighted imaging (dominant sequence for the transition zone), diffusion-weighted imaging (dominant for the peripheral zone), and dynamic contrast enhancement (which plays a supporting role). The rules for assigning the final score depend on the zone and the presence of certain features: border clarity, size, signal intensity. PI-RADS 3 indicates an uncertain result, PI-RADS 4 and 5 indicate the need for biopsy.
The need for unification arose in the early 2000s with the increasing use of mpMRI. The first PI-RADS version was released by ESUR in 2012 but was imperfect due to convoluted algorithms. In 2015, together with the American College of Radiology (ACR) and the AdMeTech Foundation, version 2 was presented, simplifying the rules and separating the approach for the transition and peripheral zones. In 2019, an interdisciplinary expert group released PI-RADS v2.1, refining criteria for the transition zone (for example, removing the 2+1 score, relaxing requirements for nodule shape), which increased specificity. PI-RADS is recognized as an international standard, and its validation continues in different populations.
After obtaining mpMRI images, the radiologist evaluates each finding sequentially:
1. Determine the zone (peripheral or transition) using T2 anatomy.
2. Peripheral zone: primary DWI assessment. DWI score: 1 — no changes, 2 — linear/wedge-shaped vague hypointensity, 3 — focal moderate hypointensity (indistinct, small), 4 — distinctly hypointense lesion <1.5 cm, 5 — distinctly hypointense lesion ≥1.5 cm or with extracapsular extension. For DWI score 3 — assess DCE: if there is focal enhancement occurring earlier than or simultaneously with the peak of normal tissue, then the final PI-RADS category is 4; if negative — 3. For DWI score 4 or 5, the category corresponds to the DWI score regardless of DCE.
3. Transition zone: primary T2 assessment. T2 score: 1 — homogeneous transition zone, 2 — nodules with a clear capsule or chondroid nodules, 3 — moderate inhomogeneity with indistinct margins, 4 — lenticular, irregular, indistinct lesion, 5 — same lesion with invasive features or ≥1.5 cm. For T2 score 2 or 3 — consider DWI: if DWI ≥4 (distinct restricted diffusion <1.5 cm), then the category is upgraded to 3 or 4 respectively. DCE does not affect the transition zone.
Size is measured by the largest diameter on an axial image. If there are multiple findings, an index lesion (the most suspicious) may be given. The report includes a map indicating the PI-RADS score of each finding.
The PI-RADS classification standardizes MRI reports, reducing interpretation variability and guiding decisions on the need for biopsy: for PI-RADS 1-2, biopsy is usually not needed; for 3, at discretion; for 4-5, mandatory.
PI-RADS version 2.1 clarified that lesions smaller than 1 cm in the transition zone cannot receive a score higher than 3, which reduced overdiagnosis.






















